AUTHORS
Michael Wang, MD, Preetesh Jain, MBBS, MD, DM, PhD2, Yu-Han Chen, MD3, Hun Ju Lee, MD4, Luis E. Fayad, MD5, Frederick B. Hagemeister, MD6, Ranjit Nair, MD7, Swaminathan P. Iyer, MD8, Chijioke C Nze, MD, MPH9, Mark P Hamilton, MD10, Maria Badillo, MSN, RN, OCN, CCRP11, Lei Feng, MS12, Guofan Xu, MBBS, PhD13, Nicolaus Wagner-Bartak, MD14, Selvi Thirumurthi, MD15, David Santos, MD, MS, FACS16, Guilin Tang, MD, PhD,FACMG17, Wendy Chen, PA18, Onyeka Oriabure, MS, APRN, FNP-C, AOCNP19, Danielle Jamison, MS20, Michelle Avellaneda21, Christopher R. Flowers Jr, MD, MS22, Jason Westin, MD, MS, FACP, FASCO23, Fateeha Furqan, MBBS24
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Mays Cancer Center, San Antonio, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: The WINDOW-1 study previously demonstrated high efficacy and a favorable safety profile for ibrutinib and rituximab (IR) induction in treatment-naïve, young patients with mantle cell lymphoma (MCL). We report long-term outcomes for the study and the impact of adding maintenance therapy for high-risk patients (HR pts).
Methods: This single-center, open-label, single-arm, phase II trial enrolled young patients ≤ 65 years with untreated MCL. Treatment consisted of part A (IR induction) and part B (consolidation with 4 abbreviated cycles of rituximab-modified hyper-CVAD alternating with methotrexate-cytarabine). A protocol amendment added part C, providing IR maintenance therapy for HR pts. The primary objective of the WINDOW-1 protocol is to evaluate the response rate of IR in young newly diagnosed MCL patients. The secondary objectives in the entire WINDOW-1 patient population and in HR pts after two years of maintenance therapy include to 1) evaluate progression-free survival (PFS), 2) estimate the duration of response (DOR) and overall survival (OS), and, specific to HR pts participating in part C and this analysis, 3) estimate the complete response (CR) rate, and 4) expand the toxicity profile of IR. We present the longer follow-up of time-to-event analysis and the impact of IR maintenance therapy in HR pts. September 15, 2025, was the data cutoff for these analyses. Alive patients were censored at their last follow-up date, and events included both progression and death. Statistical software SAS 9.4 (SAS, Cary, NC) and S-Plus 8.2 (TIBCO Software Inc., Palo Alto, CA) were used for all the analyses.
Results: One hundred and thirty-one patients were enrolled in the WINDOW-1 study. With a median follow-up of 88 months (95% CI 84–98), the median PFS, OS, and DOR have not been reached. The estimated 7-year PFS was 62% (95% CI 54–71), and the estimated 7-year OS was 84% (95% CI 77–91). Thirty-eight patients (29%) had disease progression. Two deaths occurred on-study during follow-up. Among the HR pts (n=40), all were in CR prior to maintenance therapy (median time to best response: 5 months, IQR 4–7). HR pts received IR maintenance for a median of 24 months (IQR 17–26) after completion of part A and part B. At the last on-study assessment, 36 patients (90%) remained in sustained CR (i.e., a score of 1, 2, or 3 on 5-points scale with or without a residual mass for PET-CT based responses, or regression of target nodes/nodal masses to < 1.5 cm in longest diameter with no extra lymphatic disease sites for CT-based responses), while four patients (10%) experienced disease progression on-study. Patients were followed every 4 months for 2 years, then every 6 months for 2 years, and then yearly. During maintenance, the most frequent grade 3-4 adverse events experienced by HR pts were lymphocytopenia (n=3, 8%), neutropenia (n=2, 5%), COVID-19 (n=2, 5%), headache (n=2, 5%), hypertension (n=2, 5%), and paresthesia (n=2, 5%).
Conclusion: Long-term follow-up of the WINDOW-1 strategy confirms that IR-based induction, followed by consolidation and risk-adapted maintenance, yields durable remissions and long-term survival in young patients with MCL, including those with high-risk features.
DISCLOSURES
Michael Wang, MD: SOHO Asia - Honoraria; CAHON - Honoraria; UPMC Hillman Cancer Center - Honoraria; Scientific Education Support, MJH Life Sciences - Honoraria; Genentech - Honoraria; Lymphoma Research Foundation - Honoraria; Veteran Affairs Office - Honoraria; MD Education - Honoraria; Genentech - Honoraria; Ottawa Hospital - Honoraria; Scholars in Medicine - Honoraria; AstraZeneca - Honoraria; BeOne Medicines, Ltd - Honoraria; Scientific Education Support - Honoraria; Kite Pharma - Honoraria; Scripps - Honoraria; Hospital Sirio Libanes - Honoraria; Eli Lilly - Research Funding; Nurix Therapeutics - Research Funding; InnoCare - Research Funding; Bantam Pharma - Research Funding; Loxo Oncology - Research Funding; Kite Pharma - Research Funding; Velosbio - Research Funding; AbbVie - Research Funding; Incyte - Research Funding; Juno Therapeutics - Research Funding; Genentech - Research Funding; Pharmacyclics - Research Funding; Genmab - Research Funding; Inctye - Research Funding; Oncternal Therapeutics - Research Funding; AstraZeneca - Research Funding; Janssen - Research Funding; BeOne Medicines, Ltd - Research Funding; OncLive - Patents & Royalties; BMS - Consultancy (Includes expert testimony); BeOne Medicines, Ltd - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Kite Pharma - Consultancy (Includes expert testimony); InnoCare - Consultancy (Includes expert testimony); Galapagos NV - Consultancy (Includes expert testimony); Pepromene Bio - Consultancy (Includes expert testimony)